VINC
Vincerx Pharma, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.02
+0.00%Price chart
Oct 2Oct 7Oct 12Oct 15Oct 20Oct 23Oct 28Nov 4
Key dataNov 4, 2026
Open$0.02
From 52W high−42.31%
Volume428.00
Market cap$78514.18
P/E (TTM)—
P/S (TTM)0.1x
Div yield—
Key dataNov 4, 2026
Open
$0.02
From 52W high
−42.31%
Volume
428.00
Market cap
$78514.18
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
0.2x
P/E (TTM)
—
RSI (14)
43.3
MomentumView details →
1D Return
+0.00%
YTD Return
+15.38%
SummaryUpdated Mar 1, 2025
Vincerx Pharma, Inc. (NASDAQ:VINC) is a clinical-stage biopharmaceutical company founded in 2019 and headquartered in Palo Alto, California. The company went public in May 2020 and focuses on researching and developing novel cancer therapies to address unmet medical needs. Vincerx operates in the highly specialized field of oncology drug development, with a particular emphasis on targeting specific cellular mechanisms involved in cancer progression. The company is currently in the clinical and preclinical stages of development, with no approved products generating revenue yet.
Similar companies
Latest newsMore news →
No recent news for VINC.